Table 1.
Age-adjusted* prevalence for IGT and IFG in adults aged 20–79 years globally and by IDF region
| Rank | IDF region | 2021 | 2045 | ||
|---|---|---|---|---|---|
| Prevalence, % | No. of people with condition, millions | Prevalence, % | No. of people with condition, millions | ||
| IGT | |||||
| World | 9.1 (7.9, 10.8) | 464 (404, 552) | 10.0 (8.6, 11.7) | 638 (548, 752) | |
| 1 | NAC | 13.1 (10.8, 13.6) | 47 (39, 49) | 13.8 (11.0, 14.4) | 57 (46, 59) |
| 2 | SACA | 11.6 (10.7, 12.5) | 40 (37, 43) | 12.8 (11.8, 13.8) | 53 (49, 57) |
| 3 | WP | 11.1 (9.9, 13.2) | 193 (172, 229) | 11.8 (10.8, 13.7) | 213 (195, 248) |
| 4 | MENA | 10.6 (9.7, 11.9) | 48 (43, 54) | 11.5 (10.5, 12.9) | 81 (74, 91) |
| 5 | AFR | 9.7 (6.6, 12.6) | 51 (35, 66) | 11.1 (7.3, 14.3) | 117 (77, 151) |
| 6 | EUR | 5.9 (4.9, 8.8) | 39 (33, 59) | 6.2 (5.2, 9.3) | 41 (35, 62) |
| 7 | SEA | 4.5 (4.4, 5.0) | 47 (45, 52) | 5.7 (5.5, 6.2) | 77 (74, 83) |
| IFG | |||||
| World | 5.8 (5.4, 6.3) | 298 (275, 324) | 6.5 (6.0, 7.1) | 414 (382, 452) | |
| 1 | SEA | 9.4 (9.0, 9.8) | 97 (93, 101) | 9.6 (9.1, 10.1) | 128 (122, 135) |
| 2 | MENA | 7.9 (7.5, 8.3) | 35 (33, 37) | 8.5 (8.1, 9.0) | 60 (57, 63) |
| 3 | NAC | 7.6 (7.0, 8.2) | 28 (25, 30) | 8.0 (7.4, 8.7) | 33 (31, 36) |
| 4 | AFR | 5.7 (5.3, 6.2) | 30 (28, 33) | 6.3 (5.9, 6.9) | 67 (62, 72) |
| 5 | SACA | 5.0 (4.1, 5.7) | 17 (14, 20) | 5.6 (4.6, 6.5) | 23 (19, 27) |
| 6 | EUR | 4.8 (4.2, 5.6) | 32 (28, 38) | 5.2 (4.5, 6.1) | 34 (30, 41) |
| 7 | WP | 3.4 (3.1, 3.8) | 60 (54, 66) | 3.8 (3.4, 4.3) | 69 (62, 78) |
CI are reported in parentheses. IGT was defined as 2-h postload glucose levels of 7.8–11.1 mmol/L (140–199 mg/dL). IFG was defined as fasting plasma glucose levels of 6.1 to 6.9 mmol/L (110–125 mg/dL). AFR, Africa; EUR, Europe; MENA, Middle East and North Africa; NAC, North America and Caribbean; SACA, South and Central America; SEA, Southeast Asia; WP, Western Pacific.
*
Age adjustment was based on United Nations age distribution data for each country.